search
Back to results

Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial (EXTEND-IA)

Primary Purpose

Ischemic Stroke

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Intra-arterial Clot Retrieval with Solitaire device
intravenous tissue plasminogen activator (tPA)
Sponsored by
Neuroscience Trials Australia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ischemic Stroke

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients presenting with anterior circulation acute ischaemic stroke eligible using standard criteria to receive IV tPA within 4.5 hours of stroke onset
  2. Patient, family member or legally responsible person depending on local ethics requirements has given informed consent
  3. Patient"s age is ≥18 years
  4. Intra-arterial clot retrieval treatment can commence (groin puncture) within 6 hours of stroke onset.

    Imaging inclusion criteria

    Dual target:

  5. Arterial occlusion on CTA or MRA of the ICA, M1 or M2
  6. Mismatch - Using CT or MRI with a Tmax >6 second delay perfusion volume and either CT-rCBF or DWI infarct core volume. a) Mismatch ratio of greater than 1.2, and b) Absolute mismatch volume of greater than 10 ml, and. c) Infarct core lesion volume of less than 70mL

Exclusion Criteria:

  1. Intracranial haemorrhage (ICH) identified by CT or MRI
  2. Rapidly improving symptoms at the discretion of the investigator
  3. Pre-stroke mRS score of ≥ 2 (indicating previous disability)
  4. Inability to access the cerebral vasculature in the opinion of the neurointerventional team
  5. Contra indication to imaging with MR with contrast agents
  6. Participation in any investigational study in the previous 30 days
  7. Any terminal illness such that patient would not be expected to survive more than 1 year
  8. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
  9. Pregnant women
  10. Previous stroke within last three months
  11. Recent past history or clinical presentation of ICH, subarachnoid haemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm. At the discretion of each Investigator.
  12. Current use of oral anticoagulants and a prolonged prothrombin time (INR > 1.6)
  13. Use of heparin, except for low dose subcutaneous heparin, in the previous 48 hours and a prolonged activated partial thromboplastin time exceeding the upper limit of the local laboratory normal range.
  14. Use of glycoprotein IIb - IIIa inhibitors within the past 72 hours. Prior use of single or dual agent oral platelet inhibitors (clopidogrel and/or low-dose aspirin) is permitted.
  15. Clinically significant hypoglycaemia.
  16. Uncontrolled hypertension defined by a blood pressure > 185 mmHg systolic or >110 mmHg diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring aggressive treatment to reduce the blood pressure to within these limits. The definition of "aggressive treatment" is left to the discretion of the responsible Investigator.
  17. Hereditary or acquired haemorrhagic diathesis
  18. Gastrointestinal or urinary bleeding within the preceding 21 days
  19. Major surgery within the preceding 14 days which poses risk in the opinion of the investigator.
  20. Exposure to a thrombolytic agent within the previous 72 hrs

Sites / Locations

  • John Hunter Hospital
  • Royal North Shore Hospital
  • Royal Adelaide Hospital
  • Western Hospital
  • Austin Hospital
  • Box Hill Hospital
  • Monash Medical Centre
  • Royal Melbourne Hospital
  • Auckland Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intra-arterial Clot Retrieval after iv tPA

Standard care iv tPA

Arm Description

Outcomes

Primary Outcome Measures

Reperfusion at 24 hours (CT or MR perfusion imaging)
Favourable clinical response at 3 days(National Institutes of Health Stroke Score - NIHSS)
NIHSS - reduction >/= 8 points or reaching 0-1)

Secondary Outcome Measures

Reperfusion at 24 hrs post stroke without symptomatic intracerebral hemorrhage (CT or MR perfusion imaging)
Recanalisation at 24 hrs post stroke (CT or MR angiography)
Infarct growth within 24 hrs (CT and MRI)
Stroke severity (NIHSS) at 24 hours
Symptomatic intra-cranial hemorrhage (ECASS type 2 parenchymal hematoma on CT or MRI combined with >/=4 point deterioration in NIHSS within 36 hours of treatment).
Death due to any cause
Modified Rankin Scale (mRS) 0-1 at 3 months
Categorical shift in mRS at 3 months
NIHSS reduction 8 points or reaching 0-1 at 3 months
Modified Rankin Scale (mRS) 0-2 at 3 months

Full Information

First Posted
November 20, 2011
Last Updated
April 20, 2015
Sponsor
Neuroscience Trials Australia
search

1. Study Identification

Unique Protocol Identification Number
NCT01492725
Brief Title
Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial
Acronym
EXTEND-IA
Official Title
A Randomized Controlled Trial of Intra-arterial Reperfusion Therapy After Standard Dose Intravenous t-PA Within 4.5 Hours of Stroke Onset Utilizing Dual Target Imaging Selection.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2014
Overall Recruitment Status
Terminated
Why Stopped
On DSMB advice, trial recruitment has been halted for efficacy. F/U continues
Study Start Date
June 2012 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Neuroscience Trials Australia

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients presenting to the emergency department with acute ischaemic stroke, who are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for "dual target" major vessel occlusion and mismatch to determine their eligibility for randomisation into the trial. If the patient gives informed consent they will be randomised 50:50 using central computerised allocation to intra-arterial clot retrieval after IV tPA or IV tPA alone. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Stroke

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
70 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intra-arterial Clot Retrieval after iv tPA
Arm Type
Experimental
Arm Title
Standard care iv tPA
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Intra-arterial Clot Retrieval with Solitaire device
Intervention Description
Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
Intervention Type
Genetic
Intervention Name(s)
intravenous tissue plasminogen activator (tPA)
Intervention Description
Standard care IV tPA therapy administered as per registered product information
Primary Outcome Measure Information:
Title
Reperfusion at 24 hours (CT or MR perfusion imaging)
Time Frame
24 hours post stroke onset
Title
Favourable clinical response at 3 days(National Institutes of Health Stroke Score - NIHSS)
Description
NIHSS - reduction >/= 8 points or reaching 0-1)
Time Frame
3 days post stroke onset
Secondary Outcome Measure Information:
Title
Reperfusion at 24 hrs post stroke without symptomatic intracerebral hemorrhage (CT or MR perfusion imaging)
Time Frame
24 hours post stroke onset
Title
Recanalisation at 24 hrs post stroke (CT or MR angiography)
Time Frame
24 hours post stroke onset
Title
Infarct growth within 24 hrs (CT and MRI)
Time Frame
24 hours post stroke onset
Title
Stroke severity (NIHSS) at 24 hours
Time Frame
24 hours post stroke onset
Title
Symptomatic intra-cranial hemorrhage (ECASS type 2 parenchymal hematoma on CT or MRI combined with >/=4 point deterioration in NIHSS within 36 hours of treatment).
Time Frame
within 36 hours of intervention
Title
Death due to any cause
Time Frame
3 months
Title
Modified Rankin Scale (mRS) 0-1 at 3 months
Time Frame
3 months
Title
Categorical shift in mRS at 3 months
Time Frame
3 months
Title
NIHSS reduction 8 points or reaching 0-1 at 3 months
Time Frame
3 months
Title
Modified Rankin Scale (mRS) 0-2 at 3 months
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients presenting with anterior circulation acute ischaemic stroke eligible using standard criteria to receive IV tPA within 4.5 hours of stroke onset Patient, family member or legally responsible person depending on local ethics requirements has given informed consent Patient"s age is ≥18 years Intra-arterial clot retrieval treatment can commence (groin puncture) within 6 hours of stroke onset. Imaging inclusion criteria Dual target: Arterial occlusion on CTA or MRA of the ICA, M1 or M2 Mismatch - Using CT or MRI with a Tmax >6 second delay perfusion volume and either CT-rCBF or DWI infarct core volume. a) Mismatch ratio of greater than 1.2, and b) Absolute mismatch volume of greater than 10 ml, and. c) Infarct core lesion volume of less than 70mL Exclusion Criteria: Intracranial haemorrhage (ICH) identified by CT or MRI Rapidly improving symptoms at the discretion of the investigator Pre-stroke mRS score of ≥ 2 (indicating previous disability) Inability to access the cerebral vasculature in the opinion of the neurointerventional team Contra indication to imaging with MR with contrast agents Participation in any investigational study in the previous 30 days Any terminal illness such that patient would not be expected to survive more than 1 year Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study. Pregnant women Previous stroke within last three months Recent past history or clinical presentation of ICH, subarachnoid haemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm. At the discretion of each Investigator. Current use of oral anticoagulants and a prolonged prothrombin time (INR > 1.6) Use of heparin, except for low dose subcutaneous heparin, in the previous 48 hours and a prolonged activated partial thromboplastin time exceeding the upper limit of the local laboratory normal range. Use of glycoprotein IIb - IIIa inhibitors within the past 72 hours. Prior use of single or dual agent oral platelet inhibitors (clopidogrel and/or low-dose aspirin) is permitted. Clinically significant hypoglycaemia. Uncontrolled hypertension defined by a blood pressure > 185 mmHg systolic or >110 mmHg diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring aggressive treatment to reduce the blood pressure to within these limits. The definition of "aggressive treatment" is left to the discretion of the responsible Investigator. Hereditary or acquired haemorrhagic diathesis Gastrointestinal or urinary bleeding within the preceding 21 days Major surgery within the preceding 14 days which poses risk in the opinion of the investigator. Exposure to a thrombolytic agent within the previous 72 hrs
Facility Information:
Facility Name
John Hunter Hospital
City
New Lambton Heights
State/Province
New South Wales
ZIP/Postal Code
2305
Country
Australia
Facility Name
Royal North Shore Hospital
City
St Leonards
State/Province
New South Wales
ZIP/Postal Code
2605
Country
Australia
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Western Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3011
Country
Australia
Facility Name
Austin Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Facility Name
Box Hill Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Facility Name
Monash Medical Centre
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3168
Country
Australia
Facility Name
Royal Melbourne Hospital
City
Melbourne
State/Province
Victoria
Country
Australia
Facility Name
Auckland Hospital
City
Grafton
State/Province
Auckland
ZIP/Postal Code
1001
Country
New Zealand

12. IPD Sharing Statement

Citations:
PubMed Identifier
36289001
Citation
Sarraj A, Albers GW, Mitchell PJ, Hassan AE, Abraham MG, Blackburn S, Sharma G, Yassi N, Kleinig TJ, Shah DG, Wu TY, Hussain MS, Tekle WG, Gutierrez SO, Aghaebrahim AN, Haussen DC, Toth G, Pujara D, Budzik RF, Hicks W, Vora N, Edgell RC, Slavin S, Lechtenberg CG, Maali L, Qureshi A, Rosterman L, Abdulrazzak MA, AlMaghrabi T, Shaker F, Mir O, Arora A, Martin-Schild S, Sitton CW, Churilov L, Gupta R, Lansberg MG, Nogueira RG, Grotta JC, Donnan GA, Davis SM, Campbell BCV; SELECT, EXTEND-IA, EXTEND-IA TNK, and EXTEND-IA TNK Part-II Investigators. Thrombectomy Outcomes With General vs Nongeneral Anesthesia: A Pooled Patient-Level Analysis From the EXTEND-IA Trials and SELECT Study. Neurology. 2023 Jan 17;100(3):e336-e347. doi: 10.1212/WNL.0000000000201384. Epub 2022 Oct 26.
Results Reference
derived
PubMed Identifier
34906976
Citation
Ng FC, Churilov L, Yassi N, Kleinig TJ, Thijs V, Wu T, Shah D, Dewey H, Sharma G, Desmond P, Yan B, Parsons M, Donnan G, Davis S, Mitchell P, Campbell B. Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow). Neurology. 2022 Feb 22;98(8):e790-e801. doi: 10.1212/WNL.0000000000013210. Epub 2021 Dec 14.
Results Reference
derived
PubMed Identifier
29312109
Citation
Campbell BCV, Mitchell PJ, Churilov L, Keshtkaran M, Hong KS, Kleinig TJ, Dewey HM, Yassi N, Yan B, Dowling RJ, Parsons MW, Wu TY, Brooks M, Simpson MA, Miteff F, Levi CR, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Ang T, Scroop R, Barber PA, McGuinness B, Wijeratne T, Phan TG, Chong W, Chandra RV, Bladin CF, Rice H, de Villiers L, Ma H, Desmond PM, Meretoja A, Cadilhac DA, Donnan GA, Davis SM; EXTEND-IA Investigators. Endovascular Thrombectomy for Ischemic Stroke Increases Disability-Free Survival, Quality of Life, and Life Expectancy and Reduces Cost. Front Neurol. 2017 Dec 14;8:657. doi: 10.3389/fneur.2017.00657. eCollection 2017.
Results Reference
derived
PubMed Identifier
25671797
Citation
Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, Yan B, Dowling RJ, Parsons MW, Oxley TJ, Wu TY, Brooks M, Simpson MA, Miteff F, Levi CR, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Priglinger M, Ang T, Scroop R, Barber PA, McGuinness B, Wijeratne T, Phan TG, Chong W, Chandra RV, Bladin CF, Badve M, Rice H, de Villiers L, Ma H, Desmond PM, Donnan GA, Davis SM; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 Mar 12;372(11):1009-18. doi: 10.1056/NEJMoa1414792. Epub 2015 Feb 11.
Results Reference
derived
PubMed Identifier
24207098
Citation
Campbell BC, Mitchell PJ, Yan B, Parsons MW, Christensen S, Churilov L, Dowling RJ, Dewey H, Brooks M, Miteff F, Levi C, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Kleinig T, Scroop R, Chryssidis S, Barber A, Hope A, Moriarty M, McGuinness B, Wong AA, Coulthard A, Wijeratne T, Lee A, Jannes J, Leyden J, Phan TG, Chong W, Holt ME, Chandra RV, Bladin CF, Badve M, Rice H, de Villiers L, Ma H, Desmond PM, Donnan GA, Davis SM; EXTEND-IA investigators. A multicenter, randomized, controlled study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits with Intra-Arterial therapy (EXTEND-IA). Int J Stroke. 2014 Jan;9(1):126-32. doi: 10.1111/ijs.12206. Epub 2013 Nov 10.
Results Reference
derived

Learn more about this trial

Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial

We'll reach out to this number within 24 hrs